Acorda Therapeutics, Inc. v. Alkermes PLC

CourtCourt of Appeals for the Second Circuit
DecidedJuly 15, 2026
Docket25-1896
StatusUnpublished

This text of Acorda Therapeutics, Inc. v. Alkermes PLC (Acorda Therapeutics, Inc. v. Alkermes PLC) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Acorda Therapeutics, Inc. v. Alkermes PLC, (2d Cir. 2026).

Opinion

25-1896 Acorda Therapeutics, Inc. v. Alkermes PLC

UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT

SUMMARY ORDER

RULINGS BY SUMMARY ORDER DO NOT HAVE PRECEDENTIAL EFFECT. CITATION TO A SUMMARY ORDER FILED ON OR AFTER JANUARY 1, 2007, IS PERMITTED AND IS GOVERNED BY FEDERAL RULE OF APPELLATE PROCEDURE 32.1 AND THIS COURT’S LOCAL RULE 32.1.1. WHEN CITING A SUMMARY ORDER IN A DOCUMENT FILED WITH THIS COURT, A PARTY MUST CITE EITHER THE FEDERAL APPENDIX OR AN ELECTRONIC DATABASE (WITH THE NOTATION “SUMMARY ORDER”). A PARTY CITING A SUMMARY ORDER MUST SERVE A COPY OF IT ON ANY PARTY NOT REPRESENTED BY COUNSEL.

At a stated term of the United States Court of Appeals for the Second Circuit, held at the Thurgood Marshall United States Courthouse, 40 Foley Square, in the City of New York, on the 15th day of July, two thousand twenty-six.

PRESENT: RICHARD J. SULLIVAN, JOSEPH F. BIANCO, ALISON J. NATHAN, Circuit Judges. _____________________________________

ACORDA THERAPEUTICS, INC.,

Petitioner-Appellant,

v. No. 25-1896

ALKERMES PLC,

Respondent-Appellee, _____________________________________ For Petitioner-Appellant: GARRARD R. BEENEY (Morgan R. Knudtsen, Brooke A Rottet, on the brief), Sullivan & Cromwell LLP, New York, NY.

For Respondent- Appellee: BRIAN T. BURGESS (Christopher T. Holding, Jordan F. Block, Goodwin Procter LLP, Boston, MA, on the brief), Goodwin Procter LLP, Washington, D.C.

Appeal from a judgment of the United States District Court for the Southern

District of New York (Naomi Reice Buchwald, Judge).

UPON DUE CONSIDERATION, IT IS HEREBY ORDERED,

ADJUDGED, AND DECREED that the August 7, 2023 judgment of the district

court is AFFIRMED.

Acorda Therapeutics, Inc. (“Acorda”) appeals the district court’s judgment

denying its petition to vacate or modify an arbitral award. While that award puts

$16.5 million in Acorda’s pocket – compelling Alkermes PLC (“Alkermes”) to pay

that sum in restitution – Acorda contends that it should have received an

additional $65 million, and that the district court thus erred in confirming the

award without modifying it. We assume the parties’ familiarity with the

underlying facts, procedural history, and issues on appeal, to which we refer only

as needed to explain our decision.

2 Acorda licensed a patent from Alkermes. Although that patent expired in

2018, Acorda continued to pay royalties on it, as required by its contracts with

Alkermes. After roughly two years, however, Acorda demanded arbitration and

began making its royalty payments under protest. An arbitral tribunal of three

retired judges (the “Tribunal”) concluded that (i) as to substantive law, the

contractual clauses requiring Acorda to pay post-patent-expiration royalties were

unenforceable; and (ii) as to remedies, Acorda could recover only the roughly

$16.5 million that it had paid under protest – and not the larger sums it had

previously (and willingly) forked over – because New York’s Voluntary-Pay

Doctrine (“NYVPD”) bars recovery of sums paid “with full knowledge of the

facts.” Sp. App’x at 10, 19 (quoting Dillon v. U-A Columbia Cablevision of Westchester,

740 N.Y.S.2d 396, 397 (App. Div. 2003)). Acorda subsequently asked the district

court to modify the Tribunal’s decision so that it would receive the full amount in

restitution; the district court denied Acorda’s petition because it “failed to

establish that the Tribunal manifestly disregarded the law.” Sp. App’x at 44.

“We review a district court’s decision to confirm . . . an arbitration award . . .

de novo as to legal issues, and for clear error as to factual findings.” Smarter Tools

Inc. v. Chongqing SENCI Imp. & Exp. Trade Co., 57 F.4th 372, 378 (2d Cir. 2023). A

3 district court may vacate or modify an award only for the reasons set forth,

respectively, in Sections 10 and 11 of the Federal Arbitration Act (the “FAA”). See

T.Co Metals, LLC v. Dempsey Pipe & Supply, Inc., 592 F.3d 329, 338 (2d Cir. 2010).

Applying “a judicial gloss on the specific grounds for vacatur of arbitration awards

under [Section 10],” we have recognized that an award may also be vacated if it

exhibits “manifest disregard of the law.” Id. at 340. But this doctrine is “severely

limited,” id. (internal quotation marks omitted), and involves “[a]n extremely

deferential standard of review” that requires “[o]nly a barely colorable

justification for the outcome reached by the arbitrators,” Smarter Tools, 57 F.4th at

378 (internal quotation marks omitted). 1 Similarly, as discussed below, we have

also suggested that a district court may vacate an award if it violates “public

policy.” Schwartz v. Merrill Lynch & Co., 665 F.3d 444, 452 (2d Cir. 2011) (quoting

W.R. Grace & Co. v. Local Union 759, International Union of the United Rubber, Cork,

Linoleum & Plastic Workers, 461 U.S. 757, 766 (1983)). 2

1The district court observed that, since the Supreme Court’s decision in Hall Street Associates v. Mattel, Inc., 552 U.S. 576 (2008), the manifest-disregard doctrine “has only been recognized by the Second Circuit as a basis for vacatur, not modification.” Sp. App’x at 38. We need not resolve whether the doctrine permits modification, however, because we agree with the district court that “[i]n any event, . . . the Tribunal did not manifestly disregard the law.” Id.

2There is some ambiguity in our caselaw about whether parties may still challenge arbitral awards on public-policy grounds. See Malato v. DigitalOcean LLC, No. 25-2319 (KPF), 2026 WL 686004, at *11 (S.D.N.Y. Mar. 11, 2026) (“This Court’s review of case law in the area discloses a

4 On appeal, Acorda asserts that the Tribunal (i) manifestly disregarded

federal patent doctrine, which preempts any state law “limiting restitution”; and

(ii) “contravene[d] . . . public policy.” Acorda Br. at 18–19. While these challenges

technically arise from different doctrinal origins, they share a common element.

To show manifest disregard, petitioners must point to “well-defined” and

“explicit” law that the arbitrators ignored. Smarter Tools, 57 F. 4th at 383 (internal

quotation marks omitted). And to prevail on a public-policy challenge, they must

show that the award “violates some explicit public policy” that is “well[-]defined

and dominant” and is “ascertained by reference to the laws and legal precedents.”

Schwartz, 665 F.3d at 452 (quoting W.R. Grace, 461 U.S. at 766). 3

Acorda’s arguments thus fail unless it can demonstrate that patent law

explicitly requires a patent-holder to return royalties that its licensee paid after the

dispute among district courts regarding a federal court’s ability under the FAA to vacate an arbitral award on public[-]policy grounds.” (collecting cases)). Compare Porzig v. Dresdner, Kleinwort, Benson, N. Am. LLC, 497 F.3d 133, 139 (2d Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brulotte v. Thys Co.
379 U.S. 29 (Supreme Court, 1964)
Hall Street Associates, L. L. C. v. Mattel, Inc.
552 U.S. 576 (Supreme Court, 2008)
Schwartz v. Merrill Lynch & Co.
665 F.3d 444 (Second Circuit, 2011)
Zila, Inc. v. Tinnell
502 F.3d 1014 (Ninth Circuit, 2007)
T. CO METALS, LLC v. Dempsey Pipe & Supply, Inc.
592 F.3d 329 (Second Circuit, 2010)
Kimble v. Marvel Entertainment, LLC
135 S. Ct. 2401 (Supreme Court, 2015)
Dillon v. U-A Columbia Cablevision of Westchester, Inc.
292 A.D.2d 25 (Appellate Division of the Supreme Court of New York, 2002)
DiRussa v. Dean Witter Reynolds Inc.
121 F.3d 818 (Second Circuit, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Acorda Therapeutics, Inc. v. Alkermes PLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/acorda-therapeutics-inc-v-alkermes-plc-ca2-2026.